Associated Scientists to Help Minimize Allergies — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$34,291	27
2022	Research	$56,725	63
2021	Research	$227,221	39
2020	Research	$535,920	32
2019	Research	$100,143	28

Breakdown

Who paid Research payments · program years 2019–2023

Regeneron Pharmaceuticals, Inc. $829,042 84 payments
Takeda Pharmaceuticals U.S.A., Inc. $86,401 86 payments
Sanofi US Services Inc. $25,536 10 payments
Aimmune Therapeutics, Inc. $13,130 8 payments
GlaxoSmithKline, LLC. $190 1 payment

Studies the money was for Research payments · program years 2019–2023

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab As Adjunct to Ar101 (Peanut Oral Immunotherapy) $704,325 45 payments
A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (Eoe) $49,709 20 payments
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 Peanut Oral Immunotherapy $45,757 6 payments
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-Histaminergic Angioedema With Normal C1-Inhibitor (C1-Inh) and Acquired Angioedema (Aae) Due to C1-Inh Deficiency $31,294 42 payments
A Study to Evaluate the Efficacy of Dupilumab As An Adjunct for Subcutaneous Grass Immunotherapy to Reduce Provoked Allergic Rhinitis Symptoms Using the Nasal Allergen Challenge Model $29,251 13 payments
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-Histaminergic Angioedema With Normal C1-Inhibitor (C1-Inh) $28,230 22 payments
An Observational, Non-Interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (Empower Study) $26,877 22 payments
A Randomized, Multicenter, 3-arm, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of SAR439794 in Peanut Alle $23,135 6 payments
A Multicenter, Open-Label, Long-Term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study $9,979 5 payments
Arc008 $3,152 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.